Imricor Medical Systems (ASX:IMR) said the Na Homolce Hospital in Prague, Czech Republic, will be the third site to join its VISABL-ventricular tachycardia clinical trial, with local ethics committee approval, according to a Wednesday Australian bourse filing.
The trial is evaluating real-time magnetic resonance imaging-guided ventricular ablation.
The company's shares were up nearly 2% in recent Wednesday trade.